Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) just unveiled an announcement.
Biocytogen Pharmaceuticals announced that its partner, IDEAYA Biosciences, has received FDA clearance for an IND application to initiate a Phase 1 clinical trial of IDE034, a bispecific B7H3/PTK7 antibody-drug conjugate. This milestone underscores Biocytogen’s technical capabilities and highlights the potential of IDE034 in treating various solid tumors, marking a significant advancement in precision-targeted therapeutic strategies.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a company involved in the discovery and development of bispecific antibody-drug conjugates (ADCs) for precision treatment, focusing on providing high-quality source antibodies and exploring external licensing opportunities.
Average Trading Volume: 547,814
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.73B
See more insights into 2315 stock on TipRanks’ Stock Analysis page.